Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference
08. März 2022 07:30 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference
04. Januar 2022 16:05 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference
06. Dezember 2021 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases
30. November 2021 07:30 ET
|
Bright Minds Biosciences
— Hundreds of de novo patentable psychedelic-based compounds created through discovery program — — Company plans to announce lead molecule in first quarter of 2022 — VANCOUVER, British Columbia,...
Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”
03. November 2021 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment Conference
06. Oktober 2021 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on...
Bright Minds Biosciences Provides Scientific Update
22. September 2021 07:00 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on...
Bright Minds Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference; Shares Now Eligible for DTC Clearance
08. September 2021 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on...
Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity
18. August 2021 07:00 ET
|
Bright Minds Biosciences
-- BMB proprietary 5-HT2C agonist, BMB-101, shows efficacy in pre-clinical models of Dravet Syndrome/Epilepsy, with lower seizure duration and frequency -- -- Effect of BMB compounds was...
Bright Minds Biosciences Announces Application to List on Nasdaq
16. Juni 2021 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on...